The purpose of this study is to test the safety of Bumetanide , at different doses to find out what effects, if any, it has on people who undergo tumor TAE as part of their regular care. Bumetanide is a commonly used medication to reduce the amount of water in the body.

Inclusion Criteria:

• Patients with diagnoses of HCC according to European Association for the Study of Liver disease (EASL) criteria for diagnosis (See Appendix 1). Regional lymphadenopathy will be allowed.

  • Any virus status accepted (e.g. Hepatitis C etc.)
  • Any prior liver treatment

• Patients within unresectable HCC

• At least 18 years old

• ECOG performance status 0 or 1

• Radiographically measurable disease per mRECIST 1.1

• Meets standard of care to undergo embolization

Exclusion Criteria:

• Women who are pregnant or lactating

• Documented hypersensitivity to bumetanide or sulfonamides

• Patients with resectable HCC

• High risk for post-embolization hepatic failure:

  °Child's C cirrhosis

  °> 80% liver involvement by tumor

• Contraindication to angiography/embolization including:

  • Patients cannot receive contrast:
  • Severe allergic reaction to contrast despite premedication
  • Poor renal function not on dialysis
  • Other, based on judgment of the investigator

• ECOG score 2

• Main portal vein tumor thrombus

• BCLC D = patients with distant metastasis